Last reviewed · How we verify
AGLS
AGLS is a small molecule that targets the SGLT2 receptor.
AGLS is a small molecule that targets the SGLT2 receptor. Used for Treatment of type 2 diabetes.
At a glance
| Generic name | AGLS |
|---|---|
| Also known as | S-amlodipine, Valsartan |
| Sponsor | Ahn-Gook Pharmaceuticals Co.,Ltd |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
By inhibiting SGLT2, AGLS reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This mechanism is particularly beneficial for patients with type 2 diabetes.
Approved indications
- Treatment of type 2 diabetes
Common side effects
- Increased risk of genital mycotic infections
- Increased risk of urinary tract infections
- Hypotension
Key clinical trials
- Phase III Study to Evaluate the Efficacy and Safety of AGSAVI in Patients With Essential Hypertension Inadequately Controlled With AGLS (PHASE3)
- Phase III Study to Evaluate the Efficacy and Safety of AGSAVI in Patients With Essential Hypertension (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |